Clinical Trial Update: A Phase IIII Study of AL8326 in Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase III trial update for AL8326 in small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AL8326

Snippet

Sponsor: Advenchen Laboratories Nanjing Ltd. | Conditions: Small Cell Lung Carcinoma | Phase 3 | Status: RECRUITING